עדכון 1 מתוך 1האחרוןיום 1
FDA Approves First RAS-Targeted Pill for Metastatic Pancreatic Cancer
Daraxonrasib targets the mutation behind more than 90% of cases and nearly doubled life expectancy in its pivotal trial, a landmark for a cancer with 13% five-year survival.
מה ידענו בהתחלה
- FDA approved daraxonrasib on August 26, 2026.
- Approval was based on the pivotal randomized phase 3 RASolute 302 trial.
- Drug targets mutated RAS driving more than 90% of pancreatic cancers.
- Trial showed life expectancy nearly doubled, per USA Today.
מה שנותר פתוח אז
- No verified price, coverage terms, or out-of-pocket burden in these excerpts.
- No verified exact survival months, side-effect rates, or full label details in these excerpts.
מה שאמרנו שנעקוב אחריו
- Full RASolute 302 publication with survival, safety, and subgroup data.
- Label details, real-world tolerability, and access terms for previously treated patients.